Samarth Kulkarni's Insider Trades & SAST Disclosures
Samarth Kulkarni's most recent trade in CRISPR Therapeutics AG was a trade of 19,250 Common Shares done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Samarth Kulkarni.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 19,250 | 190,863 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 19,250 | 38,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.42 per share. | 10 Mar 2025 | 9,973 | 180,890 (0%) | 0% | 42.4 | 423,055 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 9,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 9,000 | 189,890 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 10 Mar 2025 | 4,462 | 185,428 (0%) | 0% | 43.3 | 193,294 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.21 per share. | 19 Feb 2025 | 18,360 | 171,613 (0%) | 0% | 55.2 | 1,013,564 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 13,250 | 208,541 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 13,250 | 13,250 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.05 per share. | 18 Feb 2025 | 11,640 | 196,901 (0%) | 0% | 55.1 | 640,782 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 18 Feb 2025 | 6,928 | 189,973 (0%) | 0% | 52.8 | 365,798 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.21 per share. | 24 Dec 2024 | 13,751 | 195,291 (0%) | 0% | 16.2 | 222,904 | Common Shares |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Dec 2024 | 13,751 | 0 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.10 per share. | 02 Dec 2024 | 15,000 | 181,540 (0%) | 0% | 55.1 | 826,565 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 55.43 per share. | 11 Nov 2024 | 23,121 | 203,419 (0%) | 0% | 55.4 | 1,281,597 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.27 per share. | 11 Nov 2024 | 6,879 | 196,540 (0%) | 0% | 56.3 | 387,081 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 400,000 | 400,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 8,333 | 16,667 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 8,333 | 230,833 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 13 Oct 2024 | 4,293 | 226,540 (0%) | 0% | 46.3 | 198,680 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Aug 2024 | 100,000 | 222,500 (0%) | 0% | 0 | Common Shares | |
| Centessa Pharmaceuticals p... | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 48,000 | 48,000 | - | - | Share Option (right to buy) | |
| Repare Therapeutics Inc | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Black Diamond Therapeutics... | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 19,582 | 0 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 15 Apr 2024 | 19,582 | 227,704 (0%) | 0% | 19.1 | 374,408 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 59.88 per share. | 15 Apr 2024 | 18,378 | 209,326 (0%) | 0% | 59.9 | 1,100,510 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.40 per share. | 15 Apr 2024 | 1,204 | 208,122 (0%) | 0% | 60.4 | 72,722 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 78,750 | 78,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 15 Mar 2024 | 20,000 | 228,122 (0%) | 0% | 19.1 | 382,400 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 20,000 | 19,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.97 per share. | 15 Mar 2024 | 10,613 | 217,509 (0%) | 0% | 72.0 | 763,810 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.06 per share. | 15 Mar 2024 | 9,387 | 208,122 (0%) | 0% | 73.1 | 685,818 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,250 | 213,507 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 19,250 | 57,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.26 per share. | 10 Mar 2024 | 9,802 | 203,705 (0%) | 0% | 78.3 | 767,105 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 9,000 | 212,705 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.44 per share. | 10 Mar 2024 | 4,583 | 208,122 (0%) | 0% | 74.4 | 341,159 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 13,250 | 200,627 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 13,250 | 26,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.67 per share. | 18 Feb 2024 | 6,370 | 194,257 (0%) | 0% | 79.7 | 507,498 | Common Shares |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 15 Feb 2024 | 20,000 | 207,377 (0%) | 0% | 19.1 | 382,400 | Common Shares |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 20,000 | 39,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.94 per share. | 15 Feb 2024 | 12,949 | 194,428 (0%) | 0% | 79.9 | 1,035,090 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.04 per share. | 15 Feb 2024 | 5,951 | 188,477 (0%) | 0% | 81.0 | 482,257 | Common Shares |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 81.66 per share. | 15 Feb 2024 | 1,100 | 187,377 (0%) | 0% | 81.7 | 89,831 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 29 Jan 2024 | 50,000 | 237,377 (0%) | 0% | 19.1 | 956,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 50,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 60.50 per share. | 29 Jan 2024 | 49,300 | 188,077 (0%) | 0% | 60.5 | 2,982,803 | Common Shares |
| CRISPR Therapeutics AG | Kulkarni Samarth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 61.10 per share. | 29 Jan 2024 | 700 | 187,377 (0%) | 0% | 61.1 | 42,770 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 16 Jan 2024 | 20,000 | 207,377 (0%) | 0% | 19.1 | 382,400 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 62.50 per share. | 16 Jan 2024 | 20,000 | 187,377 (0%) | 0% | 62.5 | 1,250,058 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 20,000 | 59,582 | - | - | Stock Option (Right to Buy) | |
| Repare Therapeutics Inc | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2023 | 25,000 | 79,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 30 May 2023 | 25,000 | 412,377 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.63 per share. | 30 May 2023 | 9,300 | 389,777 (0%) | 0% | 65.6 | 610,359 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 63.61 per share. | 30 May 2023 | 7,301 | 405,076 (0%) | 0% | 63.6 | 464,452 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 64.46 per share. | 30 May 2023 | 5,999 | 399,077 (0%) | 0% | 64.5 | 386,682 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.83 per share. | 30 May 2023 | 2,400 | 387,377 (0%) | 0% | 66.8 | 160,401 | Common Shares |
| Black Diamond Therapeutics... | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 25 Apr 2023 | 25,000 | 412,377 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2023 | 25,000 | 104,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.50 per share. | 25 Apr 2023 | 20,607 | 391,770 (0%) | 0% | 50.5 | 1,040,616 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.45 per share. | 25 Apr 2023 | 4,393 | 387,377 (0%) | 0% | 51.5 | 226,021 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 29 Mar 2023 | 25,000 | 412,377 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2023 | 25,000 | 129,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.37 per share. | 29 Mar 2023 | 19,719 | 392,658 (0%) | 0% | 44.4 | 874,997 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.78 per share. | 29 Mar 2023 | 5,281 | 387,377 (0%) | 0% | 44.8 | 236,506 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 188,000 | 188,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 77,000 | 77,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 11,833 | 387,821 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 11,833 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 9,000 | 18,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 9,000 | 391,463 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 5,358 | 382,463 (0%) | 0% | 43.2 | 231,573 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 4,086 | 387,377 (0%) | 0% | 43.2 | 176,597 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2023 | 25,000 | 154,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 27 Feb 2023 | 25,000 | 400,988 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 48.57 per share. | 27 Feb 2023 | 13,720 | 377,088 (0%) | 0% | 48.6 | 666,415 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 47.71 per share. | 27 Feb 2023 | 10,180 | 390,808 (0%) | 0% | 47.7 | 485,710 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 49.20 per share. | 27 Feb 2023 | 1,100 | 375,988 (0%) | 0% | 49.2 | 54,118 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 13,250 | 382,361 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 13,250 | 39,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.26 per share. | 18 Feb 2023 | 6,373 | 375,988 (0%) | 0% | 48.3 | 307,561 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 25,000 | 179,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 27 Jan 2023 | 25,000 | 394,111 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 51.54 per share. | 27 Jan 2023 | 23,200 | 369,111 (0%) | 0% | 51.5 | 1,195,712 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.60 per share. | 27 Jan 2023 | 1,800 | 392,311 (0%) | 0% | 50.6 | 91,086 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.81 per share. | 06 Dec 2022 | 58,233 | 369,111 (0%) | 0% | 1.8 | 105,402 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 58,233 | 0 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 40,000 | 330,279 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 40,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.26 per share. | 03 Dec 2022 | 19,401 | 310,878 (0%) | 0% | 52.3 | 1,013,896 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2022 | 25,000 | 229,582 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.12 per share. | 28 Nov 2022 | 25,000 | 315,279 (0%) | 0% | 19.1 | 478,000 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.58 per share. | 28 Nov 2022 | 17,118 | 298,161 (0%) | 0% | 53.6 | 917,246 | Common Shares |
| CRISPR Therapeutics AG | Samarth Kulkarni | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 54.85 per share. | 28 Nov 2022 | 5,572 | 292,589 (0%) | 0% | 54.8 | 305,598 | Common Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges